key: cord-0998106-yz154qjd authors: Akhvlediani, Tamar; Jelcic, Ilijas; Taba, Pille; Pfausler, Bettina; Steiner, Israel; Sellner, Johann title: What did we learn from the previous coronavirus epidemics and what can we do better: a neuroinfectiological point of view date: 2020-06-11 journal: Eur J Neurol DOI: 10.1111/ene.14395 sha: 64c8af42f0de1a4a2b8bdf6d37e6c05bcba26cf7 doc_id: 998106 cord_uid: yz154qjd We are learning gradually about the neurologic manifestations during the ongoing coronavirus disease 2019 (COVID)‐19 pandemic, a respiratory disease related to severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2). As the clinical evidence is still limited, it makes a sense to critically analyze the spectrum of neurologic involvement caused by SARS‐CoV‐1 and Middle East respiratory syndrome coronavirus (MERS‐CoV), which were causal for epidemics in 2003 and 2012, respectively. We are learning gradually about the neurologic manifestations during the ongoing coronavirus disease 2019 (COVID)-19 pandemic, a respiratory disease related to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) [1] . As the clinical evidence is still limited, it makes a sense to critically analyze the spectrum of neurologic involvement caused by SARS-CoV-1 and Middle East respiratory syndrome coronavirus (MERS-CoV), which were causal for epidemics in 2003 and 2012, respectively. Coronaviruses belong to a family of enveloped, single-stranded RNA viruses which have the ability to cross the species barrier to infect humans and other animals [2] . The first detection of coronaviruses in the human central nervous system (CNS) dates back to 1980, when the virus was isolated on brain autopsy in two patients with multiple sclerosis [3] . In the meantime we have learned that SARS-CoV-2 is the seventh coronavirus known to infect humans, and bats and pangolins could be the natural reservoirs and intermediate animal species [2] . MERS-CoV is capable of infecting human neuronal cells in in-vitro but its receptor dipeptidyl peptidase 4 (DDP4) has a low expression in the brain [4] . So far, this virus has not been isolated in neural tissues or cerebrospinal fluid (CSF) of affected human beings. In contrast, several routes of CNS entry and infection of neurons have been reported in experimental animal models for SARS-CoV-1, which shares the receptor for cell entry with SARS-CoV-2 but binds with a 10-20-fold lower affinity [4] . Here, we performed a systematic analysis of available evidence of neurologic manifestation during the respective outbreaks using appropriate search criteria; the findings are shown in Table 1. A systematic review was carried out to study cases reporting nervous system involvement in patients with SARS-CoV1 and MERS-CoV infection. We searched PubMed and Google Scholar databases for papers This article is protected by copyright. All rights reserved All these neuromuscular disorders were evaluated as critical illness neuropathy and myopathy [7, 8] . A group from Singapore reported five cases of large artery cerebral infarctions among 206 patients with SARS-CoV-1. Two of them remained critically-ill and three died. Significant hypotension was present just before the onset of stroke in four patients [9] . confirmed cases of MERS-CoV disease [10] . One patient died from intracerebral hemorrhage, which was the result of thrombocytopenia, disseminated intravascular coagulation, and platelet dysfunction. The other patient had critical illness polyneuropathy complicating a stay at the intensive care unit (ICU). Another group reported three additional patients with MERS and neurologic disorders [11] . These were acute disseminated encephalomyelitis, bilateral anterior circulation ischemic stroke and encephalitis. Four out of 23 MERS patients in a designated hospital had neurologic complications [12] . The diagnoses included Bickerstaff's encephalitis/Guillain-Barré syndrome, intensive-care-unit-acquired weakness, and toxic or infectious This article is protected by copyright. All rights reserved neuropathies. The neurologic symptoms started 2-3 weeks after the onset of respiratory symptoms. If investigated, none of the MERS cases had a positive PCR in CSF. The review of available evidence yielded only a limited number of neurologic cases. In addition, prospective data collection or epidemiologically relevant analyses were not performed from a neurological point of view. The main finding is the neuroinvasive potential of SARS-CoV-1 with detection of the virus in CSF. Interestingly, cases with typical encephalitic symptoms or corresponding radiological features were not reported. On the other hand, the MERS cases had a time lag from respiratory to neurological symptoms and no detection of virus in CSF, which resembles a parainfectious mechanism. The MERS case with brain hemorrhage could also be of relevance for SARS-CoV-2 patients with coagulation abnormalities. neuropathies, but the possibility of direct attack by SARS-CoV-1 on the nerve could not be excluded. Multiple factors may be contributing to the vascular insult in coronavirus infection, including hypercoagulable status related to coronavirus, septic and cardiogenic shock, and possible vasculitis. The relationship between SARS and MERS and above neurological problems still needs further clarification [13] . We do see a significant reporting bias and a negligible involvement of neurologists in the previous epidemics. Now, in the wake of COVID-19, we can question what we could do better from a strategic neuroinfectiological viewpoint. We not only want to get insights to the clinical spectrum and course of infectious and parainfectious manifestations from adequately confirmed cases. This can be assured by active involvement of neurologists in the care of COVID-19 patients [14] . Concerted efforts to collect patient data including the EANCore initiative could expand the knowledge about susceptibility, prognostic factors and shortcomings of the current patient care. Key to this goal is a standardized reporting as well as diagnostic procedures with state-of-the art laboratory exam, neuroimaging and exclusion of differentials. In addition, as long as the spectrum Neuro-COVID-19 or COVID-19 associated neurological disorders is not well characterized, a permissive strategy for CSF examination and PCR testing for SARS-CoV-2 seems reasonable. A list of considerations for clinical symptoms and constellations, in which CSF diagnostics in SARS-CoV-2 positivepatients could be of relevance, is shown in Table 2 . Also, neuropathology and CSF data banking could provide valuable insights to be better prepared for upcoming neuroinfectious challenges. This article is protected by copyright. All rights reserved Neurologic Features in Severe SARS-CoV-2 Infection The proximal origin of SARS-CoV-2 Two coronaviruses isolated from central nervous system tissue of two multiple sclerosis patients Does SARD-CoV-2 invade the brain? Translational lessons from animal models Detection of SARS coronavirus RNA in the cerebrospinal fluid of a patient with severe acute respiratory syndrome Possible central nervous system infection by SARS coronavirus Neuromuscular disorders in severe acute respiratory syndrome Peripheral nerve disease in SARS:: report of a case Large artery ischaemic stroke in severe acute respiratory syndrome (SARS) Neurological Complications of Middle East Respiratory Syndrome Coronavirus: A Report of Two Cases and Review of the Literature Severe neurologic syndrome associated with Middle East respiratory syndrome corona virus (MERS-CoV) Accepted Article This article is protected by copyright. All rights reserved Neurological Complications during Treatment of Middle East Respiratory Syndrome Neurological manifestations in severe acute respiratory syndrome The need for neurologists in the care of COVID-19 patients Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium